<DOC>
	<DOCNO>NCT00558259</DOCNO>
	<brief_summary>The primary efficacy objective evaluate whether dabigatran etexilate superior placebo long-term prevention recurrent symptomatic venous thrombo-embolism ( VTE ) patient symptomatic deep-vein thrombosis ( DVT ) pulmonary embolism ( PE ) complete 6 18 month treatment vitamin K antagonist ( VKA ) .</brief_summary>
	<brief_title>Twice-daily Oral Direct Thrombin Inhibitor Dabigatran Etexilate Long Term Prevention Recurrent Symptomatic VTE</brief_title>
	<detailed_description />
	<mesh_term>Thromboembolism</mesh_term>
	<mesh_term>Venous Thromboembolism</mesh_term>
	<mesh_term>Thrombin</mesh_term>
	<mesh_term>Dabigatran</mesh_term>
	<mesh_term>Antithrombins</mesh_term>
	<criteria>Inclusion criterion : 1 . Patients confirm symptomatic PE proximal DVT leg ( ) treat 6 18 month therapeutic dosage ( intend INR 23 ) oral VKA ( e.g . warfarin , acenocoumarol , phenprocoumon , fluindione ) RECOVER study medication moment screen current study . 2 . Written inform consent Exclusion criterion : 1 . Younger 18 year age 2 . Indication VKA DVT and/or PE 3 . Patients anticoagulant treatment index PE DVT continue 4 . Active liver disease liver disease decrease survival ( e.g . acute hepatitis , chronic active hepatitis , cirrhosis ) ALAT &gt; 3 x ULN 5 . Creatinine clearance &lt; 30 ml/min 6 . Acute bacterial endocarditis 7 . Active bleeding high risk bleeding . 8 . Uncontrolled hypertension ( investigator judgement ) 9 . Intake another experimental drug within 30 day prior randomization study 10 . Life expectancy &lt; 6 month 11 . Childbearing potential without proper contraceptive measures* , pregnancy breast feeding</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2014</verification_date>
</DOC>